Editas Medicine, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

6 Mar 2025

EDIT

10-K: Editas Medicine Reports Fiscal Year 2024 Results, Outlines Strategic Priorities Through 2027

Editas Medicine's 10-K filing summarizes the company's financial performance for fiscal year 2024 and outlines its strategic priorities through 2027, focusing on in vivo gene editing and pipeline advancement.

NASDAQ

28 Feb 2024

EDIT

Editas Medicine, INC

10-K: Editas Medicine, Inc. Outlines Capital Structure and Strategic Direction in 10-K Filing

Editas Medicine's 10-K filing details its capital structure, ongoing clinical trials for gene editing therapies, and strategic partnerships aimed at advancing its pipeline.